All data are based on the daily closing price as of May 7, 2025
h
Handa Pharmaceuticals
6620.TWO
2.43 USD
-0.05
-2.02%
Overview
Last close
2.43 usd
Market cap
342.59M usd
52 week high
6.26 usd
52 week low
1.57 usd
Target price
6.6 usd
Valuation
P/E
22.2552
Forward P/E
N/A
Price/Sales
11.8194
Price/Book Value
3.7042
Enterprise Value
321.74M usd
EV/Revenue
11.7436
EV/EBITDA
19.9046
Key financials
Revenue TTM
32.09M usd
Gross Profit TTM
32.05M usd
EBITDA TTM
17.46M usd
Earnings per Share
0.11 usd
Dividend
N/A usd
Total assets
N/A usd
Net debt
N/A usd
About
Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States and China. The company offers ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; Tascenso ODT for the treatment of multiple sclerosis; and HND-033 and HND-027 for oncology diseases. It also provides Quetiapine XR to treat Schizophrenia; Dexlansoprazole DR capsules to treat erosive esophagitis and heartburn associated with symptomatic non-erosive gastroesophageal reflux disease; HND-004 for treating diabetes; HND-032 for smoking cessation; and HND-026, a GI drug. The company was founded in 2014 and is headquartered in Tainan City, Taiwan.